We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
4,522.75 -4.75 (-0.10%) Dow Futures
34,991.00 -21.00 (-0.06%) Nasdaq Futures
15,854.00 -41.75 (-0.26%) Russell 2000 Futures
1,803.50 +1.10 (+0.06%) Crude Oil
76.49 +0.60 (+0.79%) Gold
1,981.40 -3.30 (-0.17%)
Mirati Therapeutics, Inc. (MRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 56.38 |
| Open | 56.40 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 1100 |
| Day's Range | 56.39 - 56.73 |
| 52 Week Range | 27.30 - 101.30 |
| Volume | |
| Avg. Volume | 2,286,453 |
| Market Cap | 3.967B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -12.18 |
| Earnings Date | Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.69 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Related Research
- Mirati Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat2 years agoArgus Research
- Reuters
UPDATE 1-Mirati's lung cancer drug gets EU's regulatory backing
Mirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer. The European Medicine Agency's committee backed Krazati following a re-examination of the drug the panel had declined to back for authorization in July, saying the requirements for conditional support were not fulfilled, which Mirati had disagreed with. Krazati received the U.S. Food and Drug Administration's accelerated approval last year and also the UK health regulator's authorization earlier this month.
PR NewswireMirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure, the Company has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy.
ZacksMirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations
Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.
- Investing.com
Paramount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cuts
BofA on Monday downgraded media conglomerate Paramount Global (NASDAQ:PARA) by two notches - to Underperform from Buy - with a price target of $9.00 (from $32.00).
- PR Newswire
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.
- PR Newswire
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization approval for KRAZATI® (adagrasib) as a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRASG12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/o
GlobeNewswireKura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
– Ongoing Phase 1 dose-escalation trial of KO-2806 (FIT-001) expected to begin dosing patients in combination with adagrasib by mid-2024 –SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreeme
InvestorPlace7 Healthcare Stocks That Can Cure a Lackluster Portfolio
This hasn’t been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index. In many ways healthcare stocks have been suffering the hangover effects of the Covid-19 pandemic when many pharmaceutical companies and healthcare providers saw their share prices more than triple in only a few years. While the performance in 2023 has been subpar, that could soon change with momentum and sentiment swinging back in favor of
- PR Newswire
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2 study evaluating adagrasib combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation at the European Society of Medical Oncology Congress (ESMO) 2023. These data demonstrate a manageable safety profile and early signs of durability of adagrasib in combination with a checkpoint inhibitor in the first-line
Motley FoolIs Bristol Myers Squibb Stock a Buy Now?
Bristol Myers Squibb recently announced an acquisition that should strengthen its oncology portfolio.
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BPMC Blueprint Medicines Corporation | |||
| RARE Ultragenyx Pharmaceutical Inc. | |||
| APLS Apellis Pharmaceuticals, Inc. | |||
| MDGL Madrigal Pharmaceuticals, Inc. | |||
| KURA Kura Oncology, Inc. |
Similar to MRTX
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| BPMC Blueprint Medicines Corporation | |||
| IMVT Immunovant, Inc. | |||
| APLS Apellis Pharmaceuticals, Inc. | |||
| IONS Ionis Pharmaceuticals, Inc. | |||
| CYTK Cytokinetics, Incorporated |
Analyst Price Targets (16)
Upgrades & Downgrades
| Downgrade | Leerink Partners: Outperform to Market Perform | 11/7/2023 | |
| Downgrade | Stifel: Buy to Hold | 11/7/2023 | |
| Downgrade | Piper Sandler: Overweight to Neutral | 10/10/2023 | |
| Downgrade | B. Riley Securities: Buy to Neutral | 10/9/2023 | |
| Upgrade | Scotiabank: Sector Underperform to Sector Perform | 10/9/2023 | |
| Downgrade | Jefferies: Buy to Hold | 10/9/2023 |
Company Profile
3545 Cray Court
San Diego, CA 92121
United States
858 332 3410
https://www.mirati.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 587
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
